Compare SUNS & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | ANIX |
|---|---|---|
| Founded | 2023 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7M | 114.0M |
| IPO Year | 2024 | 2013 |
| Metric | SUNS | ANIX |
|---|---|---|
| Price | $6.46 | $2.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $10.50 | $9.75 |
| AVG Volume (30 Days) | 102.1K | ★ 291.2K |
| Earning Date | 11-12-2026 | 09-09-2026 |
| Dividend Yield | ★ 18.90% | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $21,571,434.00 | $210,000.00 |
| Revenue This Year | $89.71 | N/A |
| Revenue Next Year | $11.95 | N/A |
| P/E Ratio | $11.76 | ★ N/A |
| Revenue Growth | ★ 102.96 | N/A |
| 52 Week Low | $5.77 | $2.32 |
| 52 Week High | $10.45 | $5.46 |
| Indicator | SUNS | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 44.52 |
| Support Level | $5.77 | $2.62 |
| Resistance Level | $7.90 | $3.09 |
| Average True Range (ATR) | 0.29 | 0.15 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 45.58 | 31.25 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.